



- (51) International Patent Classification:  
C12N 5/02 (2006.01)
- (21) International Application Number:  
PCT/US2015/063114
- (22) International Filing Date:  
1 December 2015 (01.12.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/086,526 2 December 2014 (02.12.2014) US  
14/954,335 30 November 2015 (30.11.2015) US
- (72) Inventor; and
- (71) Applicant : LOUGH, Denver, M. [US/US]; 106 S. Gilmor Street, Baltimore, MD 21223 (US).
- (74) Agents: CAHN, Maurice, U. et al.; Cahn & Samuels, LLP, 1100 17th Street N.W., Suite 401, Washington, DC 20036-4650 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))

(54) Title: METHODS FOR DEVELOPMENT AND USE OF MINIMALLY POLARIZED FUNCTION CELL MICRO-AGGREGATE UNITS IN TISSUE APPLICATIONS USING LGR4, LGR5 AND LGR6 EXPRESSING EPITHELIAL STEM CELLS




FIG. 2B

(57) Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.



**Methods for Development and Use of Minimally Polarized Function Cell  
Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6  
Expressing Epithelial Stem Cells**

5 **Priority Claim**

This PCT international application claims priority of U.S. Serial No.14/954335 filed November 30, 2015 which itself claims the benefit of U.S. Provisional Application Serial Number 62/086,526 filed December 2, 2014, which are hereby incorporated by reference.

10 **Technical Field**

The present invention relates to constructs of micro-aggregate multicellular grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications. More particularly, the invention provides a deliverable micro-aggregate multi-cellular LGR construct on a delivery vector/substrate/support/scaffold for direct application.

20 **Background**

Over the years, clinicians and researchers have searched for antimicrobial agents that not only reduce microorganism wound burden but also possess less cytotoxic side effects. From burns to both acute and chronic wounds, there is the potential for manipulation of naturally-occurring, self-derived antimicrobial peptides, in that these agents typically function through membrane permeabilization, a mechanism less likely to lead to microbial resistance. With the continued risk of infections in wounds and the advancing epidemic of bacterial resistance to current antibiotic therapies, there is a genuine need for the development of a new class of topical antimicrobial agents for use in cutaneous burns and wounds.

There are essentially four phases of wound healing that have been described over the past century: (1) hemostasis, (2) inflammatory, (3) proliferative, and (4) remodeling. These sequential phases were first defined by the types of cells that had migrated into the wound and then later by the

type of cytokines and growth factors expressed within the tissues.

With the recent progress in mesenchymal and adipose-derived stem cell isolation and transplantation, researchers have begun to study how these cells improve healing and alter expression within each stage, particularly throughout the later inflammatory to remodeling phases. Much like the mesenchymal and adipose-derived stem cells of the deeper compartment, the epithelial stem cell develops from the primordial ectoderm, which later develops the more superficial epithelial compartment and, thus, also has a potential role in cutaneous wound healing. At this time, there is limited research on how transplantation and application of isolated LGR4, LGR5 and LGR6 expressing epithelial stem cells alter wound healing gene expression.

It is known that LGR4, LGR5 and LGR6 expressing epithelial stem cell populations are often destroyed following severe full-thickness damage to the skin, leaving tissues incapable of producing a viable and self-sustaining epithelial compartment. Despite a combination of granulatory and fibrotic efforts driven by localized inflammation and subsequent chemotaxis of a spectrum of cellular entities, without the epithelial stem cell focal niche, remaining tissues are left without the regenerative potential to form a functional epithelium, hair follicle, sweat gland, or the like.

Complex full thickness injuries to human and mammalian tissues and/or complex injuries involving multiple tissue elements (skin, muscle, fat, blood vessels, nerves and bone) are difficult in nature to heal. Such injuries and subsequent resulting wounds are also difficult to treat through current wound care methods, surgical interventions with current approved technologies utilizing cells, tissues, devices, biologics, drugs and/or growth factors. A common reason for such difficulty is that the tissues remaining in or around a wounded or injured tissue bed are typically devoid of inter-dependent, necessary components: 1) cellular progenitor and/or stem cell populations; 2) extracellular matrix/scaffolding elements and substrates; and 3) a combination of interactions between and among cellular entities and substrates. Such deficiency in the cellular niche, ECM (extracellular matrix) scaffolding and related interactive interfaces subsequently results in failure to

re-generate or generate the essential multi-dimensional architecture required for cellular migration, differentiation, and tissue polarization. Without these cell-to-cell and cell-to-matrix interactions, remaining cellular entities within the wound bed, no matter their proliferative or lineage potential, are forced to provide primarily a barrier utility rather than develop a more complex, multi-tissue construct capable of recognizable "function." Consequently, the wound -- whether involving skin, muscle, fat, tendon, bone--becomes subsequently scarred, disorganized and dysfunctional.

Current applications in field of tissue engineering of cultured skin, cartilage, bone, muscle, blood vessels, nerves, lymphatics and related substitutes are largely based on a three part strategy: 1) acquiring a tissue source and harvesting cell suspension from such tissue; 2) applying these cells to a matrix or scaffold; and 3) grafting the construct onto or into a target site of a human or animal. However, in the absence of the above-identified inter-dependent, necessary components, tissue engineering applications, cell therapy applications, regenerative medicine applications, tissue healing applications and tissue transplant therapy applications do not possess the natural cellular micro-aggregate architecture needed to competently assemble functional polarized tissues. Thus, due to the lack of proper inter-dependency, progenitor cell mass and proper scaffolding prevent such constructs to be useful in therapeutic applications such as multi-compartment tissue regeneration and/or bone and muscle reconstruction.

Consequently, in part due to the foregoing, substantial efforts and resources have been directed by both industry and academics to developing synthetic tissue substitutes, autograft constructs, as well as patient-derived epidermal expansion autografts (i.e. Epicel® from Vericel Corporation of Cambridge MA.). These products, although beneficial, are often expensive and do not provide the patient with a true multi-compartment tissue construct. For example, cultured epithelial autograft (CEA) remains unable to restore both epithelial and dermal compartments seen in native skin. But in view of the absence of interdependent functioning compartments, the cultured cells are left without an expanding localized stem cell population and the evolving tissue polarization needed to develop integument -- epidermis, dermis,

glands and hair -- which truly defines skin. This failure, in turn, leads to monolayer fragility, epithelial instability, barrier breakdown, and scar.

Alternatively, the more robust acellular matrices such as Alloderm® from LifeCell Corporation, Integra® from Integra LifeSciences Corporation and DermaMatrix a product from Musculoskeletal Transplant Foundation, although excellent reconstructive options, lack those properly placed lineage specific stem cell populations which are necessary to develop functional native tissues.

The inventor herein has already written about the relatively recent recognition of LGR5 and LGR6 as markers of both intestinal and epidermal stem cells in mammals. In *Stimulation of the Follicular Bulge LGR5+ and LGR6+ Stem Cells with the Gut-Derived Human Alpha Defensin 5 Results in Decreased Bacterial Presence, Enhanced Wound Healing, and Hair Growth from Tissues Devoid of Adnexal Structures*, *Plast. Reconstr. Surg.* 132: 1159, 2013, Leucine-rich repeat-containing G-protein-coupled receptor (LGR) is a seven-pass transmembrane protein receptor with significant sequence and structural homology to the follicle-stimulating hormone, thyroid-stimulating hormone, and luteinizing hormone receptor families.

In that study, it was recognized that human alpha defensin 5 peptide significantly enhanced wound healing and reduced basal bacterial load compared with human beta defensin 1 and sulfadiazine. Human alpha defensin 5 was the only therapy to induce LGR stem cell migration into the wound bed. In addition, gene heat mapping showed significant mRNA up-regulation of key wound healing and Wnt pathway transcripts such as Wnt1 and Wisp1. So it was concluded that human alpha defensin 5 could be used for enhanced wound healing due to the observed increase of LGR stem cell migration into wound beds and associated bacterial reduction and hair production through the augmentation of key Wnt and wound healing transcripts. In short, this and other work led to the recognition of the potential for using LGR4+, LGR5+ and LGR6+ expressing epithelial stem cells in direct biomedical engineering soft tissue constructs.

### Summary of Invention

The invention provides in a first embodiment a minimally polarized micro-

aggregate multi-cellular composition including isolated living LGR expressing cells and a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber.

5 The invention provides in a further embodiment to the previous embodiment a minimally polarized micro-aggregate multi-cellular composition including isolated living LGR expressing cells and a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber where the LGR expressing cells are supplemented with growth factors and where the LGR expressing cells are selected from the group consisting of LGR4, LGR5 and LGR6.

10 The invention provides in a further embodiment to any of the previous embodiments a minimally polarized micro-aggregate multi-cellular composition including isolated living LGR expressing cells and a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber where the LGR expressing cells are supplemented with migratory/recruiting analytes and the LGR expressing cells being selected from the group consisting of LGR4, LGR5 and LGR6.

15 The invention provides in a further embodiment to any of the previous embodiments a minimally polarized micro-aggregate multi-cellular composition including isolated living LGR expressing cells and a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber where the LGR expressing cells are supplemented with LGR specific binding elements selected from the group consisting of ligand families, R-spondin, EDGF, PDGF, Wnt, VEGF, and antimicrobial peptides and where the LGR expressing cells are selected from the group consisting of LGR4, LGR5 and LGR6.

20 The invention provides in a further embodiment to any of the previous embodiments a minimally polarized micro-aggregate multi-cellular composition including isolated living LGR expressing cells and a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber where the composition is used as a therapeutic construct for a select target consisting of a tissue region, wound, void, defect tissue, or blood for alteration of either surrounding adjacent tissues.

The invention provides in a further embodiment to any of the previous embodiments a minimally polarized micro-aggregate multi-cellular composition characterized by a isolated living LGR expressing cells transplanted to damaged tissue to accelerate healing thereof.

5 The invention provides in a further embodiment to any of the previous embodiments a minimally polarized micro-aggregate multi-cellular composition for tissue system repair or restoration throughout the body comprising a support scaffolding with isolated LGR containing cells secured thereto.

10 The invention provides in a further embodiment to any of the previous embodiments a tissue graft for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body

Another embodiment of the invention is characterized by a method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue.

15 The invention provides in a further embodiment to the foregoing method a method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue further characterized by the step of affixing the isolated living LGR expressing cells to a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber.

20 The invention is characterized in still another embodiment by a method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue further characterized by the step of selecting the LGR expressing cells from the group consisting of LGR4, LGR5 and LGR6.

25 The invention provides in a further embodiment to any of the previous method embodiments the step of applying the minimally polarized micro-aggregate multi-cellular to one of the group consisting of epithelial systems, glands, hair, nerves, bone, muscle, fat, tendons, blood vessels, fascia, ocular tissues and peptide secreting cellular elements employing delivery by a technique selected from the

group consisting of application, transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating and/or injection of the cellular element generating, regenerating, enhancing and healing.

The invention provides in a further embodiment to any of the previous method  
5 embodiments a method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue further characterized by the step of applying the minimally polarized micro-aggregate multi-cellular composition directly to a tissue *in vivo* for tissue  
10 restoration.

The invention provides in a further embodiment to any of the previous method  
embodiments a method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target  
15 tissue further characterized by the step indirectly applying the minimally polarized micro-aggregate multi-cellular composition via the blood stream for tissue restoration in a body.

The invention is characterized in yet another embodiment by a method for producing a minimally polarized micro-aggregate multi-cellular composition  
20 characterized by the steps of:

- a) obtaining a tissue specimen;
- b) extracting minimally polarized functional units containing LGR expressing cells from the specimen;
- c) processing of hypodermis and subdermal fat cellular components from an  
25 appropriate source;
- d) adding the processed hypodermis and subdermal fat components to the extracted minimally polarized functional units to create epithelial stem cell singularity units;
- e) enriching the epithelial stem cell singularity units;
- 30 f) adding the epithelial stem cell singularity units to a construct scaffold; and
- g) verifying the maintenance of minimum polarization of the obtained composition.

The invention provides in a further embodiment to any of the previous

embodiments a media formulation used in obtaining minimally polarized micro-aggregate multi-cellular compositions using cell sustaining media composition for reducing the viability of micro-organisms during transport and processing of tissues, characterized by: a) a mixture of epithelial cells and keratinocytes; b) at least one agent selected from the group consisting of penicillin, streptomycin, and amphotericin B; and c) fibrinogen.

The invention provides in a further embodiment to the previous embodiment of a cell sustaining media composition for reducing the viability of micro-organisms during transport and processing of tissues, characterized by: a) a mixture of epithelial cells and keratinocytes; b) at least one agent selected from the group consisting of penicillin, streptomycin, and amphotericin B; and c) fibrinogen, where the fibrinogen is human and where the agent includes both an antibiotic and an antimycotic for stabilizing human tissues.

In the context of a first aspect of the invention, it is characterized by LGR expressing cells being applied to scaffolding matrix, and/or fiber to thereby establish micro-aggregate multi-cellular grafts for tissue engineering applications, cell therapy applications, regenerative medicine applications, medical/therapeutic applications the grafts being directly applied to tissue or blood for improvement and or alteration of epithelial systems throughout the body.

A second aspect of the invention is characterized by LGR expressing cells being applied to scaffolding, matrix, and/or fiber with or without additional enhancing factors or analytes before or after either being applied to tissue or blood for improvement and or alteration of *in vivo* epithelial systems.

A further aspect of the invention is characterized by LGR expressing cells altered by enhancing factors or analytes, being applied as targets within the body, tissue or blood for improvement and or alteration of epithelial systems through local or distant migration throughout the body and/or to restore gland and hair growth.

A fourth aspect of the invention is characterized by transplanting LGR expressing cells from tissue, blood or culture for alteration of surrounding adjacent tissues or distant tissues such as but not inclusive of LGR expressing cells applied to scaffolding, matrix, and fiber before or after either

being applied to tissue or blood for improvement and or alteration of ectodermal, mesodermal or endodermal- derived tissues systems throughout the body.

5 A fifth aspect of the invention is characterized by directly applying LGR expressing cells to a delivery substrate vehicle selected from a group consisting of scaffolding, matrix, and fiber with our without additional enhancing factors or analytes before or after either being applied to tissue or blood for improvement and or alteration of ectodermal, mesodermal or endodermal-derived tissues systems throughout the body.

10 Still another aspect of the invention is characterized by combining LGR expressing cells altered by enhancing factors or analytes, with a delivery support substrate as targets within the body, tissue or blood for improvement and or alteration of ectodermal, mesodermal or endodermal-derived tissues systems throughout the body through local or distant migration throughout  
15 the body.

A further aspect of the invention is characterized by adhering LGR expressing cells to a support substrate for the delivery, application, transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating and/or injection of the cellular element  
20 generating, regenerating, enhancing and/or healing epithelial systems, glands, hair, nerves, bone, muscle, fat, tendons, blood vessels, fascia, ocular tissues and peptide secreting cellular elements.

A final stated aspect of the invention is to generate LGR expressing stem cells as micro-aggregate multi-cellular functional units exhibiting minimal  
25 polarization for transplantation and direct application to a target within a mammalian body, tissue or blood to enhance and accelerate tissue generating, regenerating, enhancing and/or healing.

In most general terms, the invention herein contemplates the transplanting and/or delivery of isolated LGR expressing cells (Leucine-rich  
30 repeat-containing G-protein coupled receptor) for the generation, regeneration, recruitment or enhancement of an epithelial system, hair, gland bone. The invention also contemplates application to both local/proximate and distant/remote tissue in clinical medicine, bioengineering and/or research

constructs using a delivery vehicle in the form of scaffolding, matrix or fiber with or without the supplementation of growth factors migratory/recruiting analytes or LGR specific binding elements such as but not limited to ligand families: R-spondin, EDGF, PDGF, Wnt, VEGF, antimicrobial peptides.

5 Use of the LGR epithelial stem cells, particularly in conjunction with a formed scaffolding substrate, provides full thickness wounds and or voids in epithelial systems with a stem cell enriched tissue substitute. Moreover, the addition of this minimally polarized functional cell unit (MPFU) to an epithelial system is enhances/improves the status that epithelium which includes the growth, generation or regeneration of hair, glands, secreted anti-microbial peptides, growth factors and analytes generally required to maintain and promote the health and viability of the epithelium and local surrounding tissues elements.

10 Recognizing that LGR4+, LGR5+ and LGR6+ stem cell and progenitor cell proliferation kinetics remain high, especially when in contact with substrate scaffolding, complete epithelial turnover rates are typically less than 12 days (1cm inter-population distance spacing). This capacity to regenerate a sufficient tissue bi-layer and subsequent barrier function suggests a role for these cells as a type of evolving biologic dressing for complex full thickness and multi- tissue wounds.

15 Beyond a capacity to regenerate skin, muscle and bone quickly, the progenitors of the LGR4, LGR5 and LGR6 stem cells also have the ability to generate native anti-microbial peptides that not only reduce the basal level of microorganisms within the wound bed but also augment progenitor cells amplification and differentiation, leading to a reduction in wound and peri-wound infections, faster wound closure, and hair follicle development.

20 The invention herein describes the translational applicability of an LGR expressing epithelial stem cell -seeded scaffold in providing an immediate, deliverable and viable tissue barrier that is capable of maintaining a stem cell colony focus with concomitant competent progeny. From these stem cell foci, progeny can undergo migratory proliferative-differentiation in order to stimulate epithelial tissue elements, healing and graft integration. It has been found that the LGR epithelial stem cells can be applied alone, with

scaffolding, soluble growth factors and/or additional cell lineage which promote the polarization of the scaffold bound populations as well as intrinsic tissue architecture required in epithelial healing and cellular regenerative efforts.

5           Broadly defined, the protocol of the invention involves: a) harvesting living human/mammalian tissue; b) processing the tissue element to generate a micro-aggregate multi-cellular functional units which contain LGR expressing cells; c) applying the LGR expressing cell micro-aggregate multi-cellular functional units to a delivery vehicle substrate selected from the group  
10           consisting of scaffolding, matrix, particle, cell(s) and fiber to create a construct; d) optionally including selected additional enhancing factors; and e) applying the construct to tissues for generating, regenerating, enhancing and/or healing tissue systems including those related to ectodermal, mesodermal and/or endodermal origin tissues including but not limited to  
15           skin, glands, hair, nerves, bone, muscle, fat, tendons, blood vessels, fascia, ocular tissues, bone marrow, lung, heart, nails, gastrointestinal tissues, oral tissues, teeth, taste buds, urogenital tissues, renal tissues, reproductive tissues, lymphatic tissues, immune system tissues/elements and such related appendages and protein cellular elements.

20           This invention contemplates the direct delivery of supported LGR expressing epithelial stem cells by application, transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating and/or injection of the cellular element to alter mammalian tissue(s) in therapeutics, devices, biologics, drugs and bio-engineering.

## 25   **Definitions**

          In this detailed description, references to "one embodiment", "an embodiment", or "in embodiments" mean that the feature being referred to is included in at least one embodiment of the invention. Moreover, separate references to "one embodiment", "an embodiment", or "embodiments" do not  
30           necessarily refer to the same embodiment; however, neither are such embodiments mutually exclusive, unless so stated, and except as will be readily apparent to those skilled in the art. Thus, the invention can include any variety of combinations and/or integrations of the embodiments

described herein. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

As used herein, the singular forms, "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the root terms "include" and/or "have", when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of at least one other feature, step, operation, element, component, and/or groups thereof.

As used herein Bone means the hard connective tissue consisting of cells embedded in a matrix of mineralized ground substance and collagen fibers. The fibers are impregnated with inorganic components, including crystals of calcium phosphate, such that using X-ray diffraction, they are seen to be organized in a hydroxyapatite pattern (calcium phosphate is 85% by weight) as well as calcium carbonate (10%), and magnesium; by weight, bone is composed of 65–75% inorganic and 25–35% organic material; a portion of osseous tissue of definite shape and size, forming a part of the animal skeleton; in humans there are approximately 200 distinct bones in the skeleton, not including the auditory ossicles of the tympanic cavity or the sesamoid bones other than the two patellae. A bone is enveloped by a fibrous membrane, periosteum that covers the bone's entire surface except for the articular cartilage. Beneath the periosteum is a dense layer, compact bone, and beneath that a cancellous layer, spongy bone. The core of a long bone is filled with marrow.

As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having" or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of features is not necessarily limited only to those features but may include other features not expressly listed or inherent to such process, method, article, or apparatus.

For definitional purposes and as used herein "connected" includes physical, whether direct or indirect, affixed or adjustably mounted, as for

example, the communication unit is connected to the a PID controller either directly or through a conventional wireless linkage when spaced apart. Thus, unless specified, "connected" is intended to embrace any operationally functional connection.

5       As used herein Epithelium means the cellular layer covering all free surfaces, cutaneous, mucous, and serous, including the glands and other structures derived therefrom.

As used herein GMP means good manufacturing practices.

10       As used herein Integument means the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all the derivatives of the epidermis, hairs, nails, sudoriferous and sebaceous glands, and mammary glands, as well as the subcutaneous tissue.

15       As used herein LGR4 means Leucine-Rich Repeat Containing G Protein-Coupled Receptor 4, G protein-coupled receptors (GPCRs) that play key roles in a variety of physiologic functions. Members of the leucine-rich GPCR (LGR) family, such as GPR48, have multiple N-terminal leucine-rich repeats (LRRs) and a 7-transmembrane domain. LGR4 (Leucine-Rich Repeat Containing G Protein-Coupled Receptor 4) is a Protein Coding gene. Diseases associated with LGR4 include bone mineral density, low. Among its 20 related pathways are Wnt signaling pathway (KEGG). GO annotations related to this gene include G-protein coupled receptor activity and transmembrane signaling receptor activity. An important paralog of this gene is LGR6. Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and is involved in the formation of various organs. Upon binding to 25 R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes.

30       In contrast to classical G-protein coupled receptors, LGR4 does not activate heterotrimeric G-proteins to transduce the signal. Its function as activator of the Wnt signaling pathway is required for the development of various organs, including liver, kidney, intestine, bone, reproductive tract and eye. LGR4 may also act as a receptor for norrin (NDP) and is required during

spermatogenesis to activate the Wnt signaling pathway in peritubular myoid cells. Likewise, LGR4 is required for the maintenance of intestinal stem cells and Paneth cell differentiation in postnatal intestinal crypts. LGR4 also acts as a regulator of bone formation and remodeling in addition to being involved in kidney development; required for maintaining the ureteric bud in an undifferentiated state. LGR4 is involved in the development of the anterior segment of the eye, required during erythropoiesis and also acts as a negative regulator of innate immunity by inhibiting TLR2/TLR4 associated pattern recognition and pro-inflammatory cytokine production. LGR plays an important role in regulating the circadian rhythms of plasma lipids, partially through regulating the rhythmic expression of MTTP (By similarity).

Commonly known aliases for LGR4 include: GPR48; G Protein-Coupled Receptor 48; BNMD17; Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4; Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 4; and G-Protein Coupled Receptor 48. External Database Identifiers for LGR4 include: HGNC: 13299 Entrez Gene: 55366 Ensembl: ENSG00000205213 OMIM: 606666 and UniProtKB: Q9BXB.

As used herein LGR5 means Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5, a Protein Coding gene. Among its related pathways are Wnt signaling pathway (KEGG). GO annotations related to this gene include G-protein coupled receptor activity and transmembrane signaling receptor activity. An important paralog of this gene is LGR6. The LGR5 Receptor is for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, LGR5 does not activate heterotrimeric G-proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development. Commonly known aliases for LGR5 include: G-Protein Coupled Receptor HG38; G-Protein Coupled Receptor 49; G-Protein Coupled Receptor 67; GPR67;

GPR49 and Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5. External Database Identifiers for LGR5 include HGNC: 4504 Entrez Gene: 8549 Ensembl: ENSG00000139292 OMIM: 606667 and UniProtKB: O75473.

As used herein LGR6 means Leucine-Rich Repeat Containing G Protein-Coupled Receptor 6 which is a Protein Coding gene a gene that encodes a member of the leucine-rich repeat-containing subgroup of the G protein-coupled 7-transmembrane protein superfamily. The encoded protein is a glycoprotein hormone receptor with a large N-terminal extracellular domain that contains leucine-rich repeats important for the formation of a horseshoe-shaped interaction motif for ligand binding. Alternative splicing of this gene results in multiple transcript variants. Diseases associated with LGR6 include myxedema and ovarian cystadenoma. Among its related pathways are Wnt signaling pathway (KEGG) and GPCRs, Other annotations related to this gene include G-protein coupled receptor activity and transmembrane signaling receptor activity. An important paralog of this gene is TSHR. Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a marker of multipotent stem cells in the epidermis. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, LGR6 does not activate heterotrimeric G-proteins to transduce the signal and can act as a tumor suppressor. Common aliases for LGR6 include: Gonadotropin Receptor; VTS20631 and GPCR. External Database Identifiers for LGR6 include HGNC: 19719 Entrez Gene: 59352 Ensembl: ENSG00000133067 OMIM: 606653 and UniProtKB: Q9HBX8.

As used herein Mesenchyme means an aggregation of mesenchymal cells. Primordial embryonic connective tissue consisting of mesenchymal cells, usually stellate in form, supported in inter-laminar jelly.

As used herein Muscle means the primary tissue, consisting predominantly of highly specialized contractile cells, which may be classified as skeletal muscle, cardiac muscle, or smooth muscle; microscopically, the

latter is lacking in transverse striations characteristic of the other two types; one of the contractile organs of the body by which movements of the various organs and parts are effected; typical muscle is a mass of musculus fibers (venter or belly), attached at each extremity, by means of a tendon, to a bone or other structure; the more proximal or more fixed attachment is called the origin (q.v.), the more distal or more movable attachment is the insertion (q.v.); the narrowing part of the belly that is attached to the tendon of origin is called the caput or head.

As used herein Neural is intended to include any structure composed of nerve cells or their processes, or that on further development will evolve into nerve cells. Referring to the dorsal side of the vertebral bodies or their precursors, where the spinal cord is located, as opposed to hemal.

As used herein, and unless expressly stated to the contrary, "or" refers to an inclusive-or and not to an exclusive-or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

The meaning of Particle herein connotes the largest domain of which is ten micron or less and includes, but is not limited to, nanoparticles, an association of macromolecules, a micelle, a cell ghost, a dendrimer, and the like that can serve as a suitable anchor for a cell micro-aggregate.

As used herein Polarity means the tendency of a cell, tissue(s) and/or organism to develop differentially along an axis.

As used herein Pulse Rescue Media (PRM) is a formulation of a cell sustaining media mixture including Keratinocyte-SFM (1X), an antibiotic-antimycotic selected from the group consisting of penicillin, streptomycin, and amphotericin B, and fibrinogen where the Keratinocyte-SFM is composed of a mixture of epithelial cells and keratinocytes. The reagents are utilized in order to stabilize the primary tissues and reduce the viability of micro-organisms during transport and processing.

As used herein Skin means the membranous protective covering of the body, consisting of the epidermis and dermis (corium).

As used herein Stem cell means any precursor cell; a cell with daughter

cells that may differentiate into other cell types; a cell capable of maintaining its own number while exporting progeny to one or more cell lineages.

As used herein "substantially," "generally," and other words of degree are relative modifiers intended to indicate permissible variation from the characteristic so modified. It is not intended to be limited to the absolute value or characteristic which it modifies but rather possessing more of the physical or functional characteristic than its opposite, and preferably, approaching or approximating such a physical or functional characteristic.

As used herein Tissue means a collection of similar cells and the intercellular substances surrounding them. There are four basic kinds of tissue in the body: epithelium; connective tissues including adipose tissue, blood, bone, and cartilage; muscle tissue; and nerve tissue. The rind, capsule, or covering of any body or part.

In the following description, reference is made to the accompanying drawings which are provided for illustration purposes as representative of a specific exemplary embodiments in which the invention may be practiced. The following illustrated embodiment is described in sufficient detail to enable those skilled in the art to practice the invention. It is to be understood that other embodiments may be utilized and that structural changes based on presently known structural and/or functional equivalents may be made without departing from the scope of the invention.

#### **Brief Description of the Drawings**

Figure 1A depicts an example of location of said LGR expressing cells of cutaneous origin.

Figure 1B is a Fluorescent Activated Cell Sorting graph.

Figure 1C are photographs of a spectrum of various acellular supports contemplated for use in connection with the invention.

Figure 2A is photograph of a gross cellular construct/ de-cellularized collagen scaffold usable for seeding.

Figure 2B are immunofluorescent photomicrographs of a collagen construct following seeding with micro-aggregate multi-cellular functional units according to the invention.

Figure 3A - 3F present various images by different techniques of an array

of different seeded substrates according to the invention.

Figure 4A depicts a time lapse *in vivo* healing progression of controls and an example of an LGR containing construct in accordance with the invention. Figure 4B is a graphical expression of Cytokeratin-17 transcript expression at day ten. Figures 4C-E depict controls and a matrix of LGR expressing based micro-aggregate multi-cellular functional units according to the invention by bioluminescent imaging scanning electron microscopy and of an alternative matrix with silicone protective overlay.

Figures 5A-E depict an example of said construct with LGR and supportive cellular entities following initial form of polarization accompanied by a graphic comparison.

Figures 6A-B depict an example of a construct containing LGR cells with and without supportive cellular entities and the relative production of growth factors.

Figures 7A-H illustrate a wound/injury/void receiving therapy example of enhanced LGR cell migration, proliferation and viability into a third degree wound bed.

Figures 8A-Q depict time progression of a wound/injury/void with LGR as it relates to antimicrobial behavior.

Figures 9A and B are comparative photographs of LGR expressing cellular entities within a wound bed as it relates to augmented healing, tissue and appendage regeneration and subsequent hair growth in treated burn wounds devoid of adnexal structures.

Figures 10A-L comprise an example of said LGR expressing cellular entities within wound/injury/ tissue void as it relates to augmented healing, propagation of said entities.

Figures 11A and B illustrate a wound/injury/tissue void with the LGR expressing cellular entities placed within wound as it relates to augmentation of pro-healing pathways.

Figures 12A-I represent an example of a micro-aggregate multicellular unit containing LGR expressing stem cell foci as it relates to location, population identity and wound healing capacity.

Figures 13A-D are photomicrographs by confocal microscopy and

bioluminescence of a functional singularity unit (aFSU) at the time initial seeding and 1 day later.

Figures 13E is a photomicrograph of a collagen scaffold.

Figures 14A-E depict an example of location LGR cellular varieties as it relates to location, phenotype, interface and polarity within a cutaneous tissue. Isolation and culture of the LGR6+ ESC from the follicular bulge.

Figures 15A-E provides an example of LGR expressing cellular foci as it relates to a method of delivery through placement around and/or within wound/injury/tissue void.

Figures 16A-D depict an example of LGR containing stem cell focus as it relates to delivery into and around wounds via a deliverable vector and subsequent healing, regeneration of tissues and supporting structures.

Figures 17A-D show LGR6+ epithelial stem cell migration and differentiation within full-thickness wound beds 10 days after transplantation.

Figure 18 provides an RT-PCR quantification and inset gene heat mapping comparison of a wound/injury/tissue void with the LGR expressing cellular foci.

Figure 19 depicts an example of said LGR expressing cellular foci as it relates to delivery into and/or around wound/injury/tissue void and augmentation of wound healing factors.

Figures 20A-F illustrate an example of LGR expressing cellular foci as it relates to the regeneration of bone tissues. Isolated LGR foci can be seeded bone and remain viable

### Detailed Description

Figures 1A-C Example of flow cytometry of cell populations that exist around a hair follicle and scaffolds that such cells readily adhere to when seeded. More specifically, Figure 1A depicts an example of location of said LGR expressing cells of cutaneous origin. Immunofluorescent confocal microscopy at 40x magnification depicts the follicular bulge (white arrow), LGR6+ (Green), DNA (Blue). Figure 1B is a fluorescent activated cell sorting graph with gate analysis indicating exemplary cellular markers. Figure 1C depicts an array of cells types can be used to seed a spectrum of acellular matrices/substrates/scaffolds/materials according to the invention.

Figure 2A is a photographic representation of an example of a gross construct without micro-aggregate multi-cellular functional units containing LGR expressing stem cell foci in accordance with the invention. Figure 2B depicts the construct following seeding of substrate with micro-aggregate multi-cellular functional units containing LGR expressing stem cell foci in accordance with the invention.

Figure 3A, in columnar format, is an image series by differential interference contrast (DIC) confocal microscopy of LGR seeded substrates from different sources. Figure 3B is a corresponding column by immunofluorescent confocal microscopy at 20x magnification of LGR6+ ESC seeded matrices of respective constructs containing LGR expressing cells. The inset white boxes represent focal zoom regions indicated in the column Figure 3D while Figure 3C is a column depicting the Digital merge of the respective image of Figure 3A (DIC) and the immunofluorescent of Figure 3B indicating matrix contour and boundaries. The columns of Figures 3E and 3F respectively represent the bioluminescence measured in radiant efficiency of an acellular matrix control and a corresponding LGR6+ ESC seeded matrix at 72 hours post-seeding.

Figure 4A-E depict examples of said LGR containing construct placed into living mammalian system. Placement of an LGR6+ GFP ESC Seeded Matrix Augments Healing Hair Follicle Growth. Figure 4A is a 3x3 matrix of photomicrographs of 3mm full human de-cellularized dermis thickness burn wound beds at days 5, 8 and 10 containing no matrix (burn control), matrix (matrix control) and LGR6+ GFP ESC in accordance with the present invention. Figure 4B graphically depicts the relative expression of Cytokeratin-17 transcript expression at day 10 of the wound beds depicted in Figure 4A. The percent wound bed healed was determined using quantification analysis of wound bed healing rates as a percent area function within the ImageJ NCBI application. Wound control contains burn wound bed only. Matrix control contains matrix only and LGR6+ GFP contains ADM seeded with LGR6+ GFP ESCs. Figure 4C is a photomicrograph of *in vivo* bioluminescent imaging in murine full thickness burn wound beds at day 5. Figure 4D are micrographs of human dermis at 100x of the controls and LGR6+ GFP containing dermis at 12 hours and 72 hours and after seeding with ESCs. The white arrow indicates the

presence of a dermal pore Figure 4E provides images of the controls and the construct of the invention containing human dermis seeded with ESCs with a silicone protective overlay to prevent desiccation. The LGR6+ GFP matrix image includes duplicate small black arrows that indicate nascent hair patches from the full thickness Nu/Nu murine wound bed.

Figures 5A-E depict an example of said construct with LGR and supportive cellular entities following initial form of polarization as well as the effect of addition of Stromal vascular fraction (SVF) to LGR6+ ESC Seeded Matrices in promoting tissue polarization and a dual compartment skin-like System. Figure 5A is confocal 20x imaging of a  $5 \times 10^5$  RFP expressing stromal vascular fraction cellular isolate population 24 hours after being seeded on to a representative Adrenomedullin (ADM) (such as that available from Integra LifeSciences Corporation under the name Integra®). Figure 5B is a confocal 20x image of a  $5 \times 10^5$  GFP expressing LGR6+ cellular isolate population 24 hours after being seeded on to a representative ADM (Integra®). Figure 5C depicts confocal 20x imaging of a dual seeded representative ADM (Integra®) with  $5 \times 10^5$  RFP expressing SVF and  $5 \times 10^5$  GFP expressing LGR6+ isolate populations 24 hours after being co-seeded in culture. Figure 5D is of a co-seeded matrix containing  $5 \times 10^5$  RFP expressing SVF<sup>RFP</sup> and  $5 \times 10^5$  GFP expressing LGR6+ following 5 days of growth in culture. The dotted parallel lines indicate epithelial LGR6<sup>+GFP</sup> lineage accumulating at the edge of the ADM substrate. The small bracket and large bracket indicate the relative locations of the two compartments in correlation with LGR6<sup>+GFP</sup> and SVF<sup>RFP</sup> abundance. The arrowed "U" shaped solid line indicates a region containing a pre-seeded pore induced by a 32 gauge sterile needle. Figure 5E is a graphical representation of the proliferation kinetics of a collagen substrate co-seeded with green LGR expressing cells and red SVF expressing cells.

Figures 6A and 6B depict an example of a construct containing LGR cells with and without supportive cellular entities and the relative production of growth factors. Correlative Expression Profiles of Pro-angiogenic Transcripts and Protein Analytes from LGR6<sup>+GFP</sup> ESC and SVF<sup>RFP</sup> Enriched Scaffolding Culture Constructs. Figure 6A graphs relative fold transcript expression ( $\Delta\Delta CT$ ) of indicated gene element from total RNA: LGR6<sup>+GFP</sup> ESC (black bar), SVF<sup>RFP</sup>

(grey bar), and co-cultured LGR6<sup>+GFP</sup> ESC + SVF<sup>RFP</sup> (white box) on respective scaffold substrate. Significance above the x-axis (LGR6 + SVF) indicates the inter-comparison co-cultured LGR6<sup>+GFP</sup> ESC + SVF<sup>RFP</sup> expression vs. singular LGR6<sup>+GFP</sup> ESC and SVF<sup>RFP</sup> expression on indicated scaffolding. Ex. Average FGF-2 gene expression for co-cultured matrices was higher than the average expression of both singular systems (Scaffold+ LGR6 or Scaffold® +SVF) except for co-cultured Integra® (Integra+ LGR6+ SVF). Significance below the x-axis (LGR6) or (SVF) indicates the intra-comparison of substrates, while the cellular entity remains constant. Ex. VEGF-A gene expression for Integra®+ LGR6<sup>+GFP</sup> ESC only vs. Dermamatrix®+ LGR6<sup>+GFP</sup> ESC only was nonsignificant (NS). Figure 6B graphically represents the relative densitometric unit (RDU) of indicated protein analyte from total protein isolates: LGR6<sup>+GFP</sup> ESC (black bar), SVF<sup>RFP</sup> (grey bar), and co-cultured LGR6<sup>+GFP</sup> ESC + SVF<sup>RFP</sup> (white box) on respective scaffold substrate. (\*) indicates (p-value < 0.05), assays completed in triplicates, GAPDH housekeeping control.

Figures 7A-H illustrate a wound/injury/void receiving therapy example of enhanced LGR cell migration, proliferation and viability into a wound namely a third degree wound bed induction and verification of the elimination of the LGR stem cell follicular bulge and adnexal structures. Figure 7A depicts a wound bed template marks of 3mm diameter. Figure 7B depicts the wound bed structure at day 0 (the white scale bar being 1mm). Figure 7C illustrates an example of a 2x3 3mm wound bed grid. Figure 7D shows topical application of the re-suspended peptide at the wound site. Figure 7E is a photomicrograph of H&E stain of non-burned, intact Integument/skin with hair follicle and adnexal structures. The arrow indicates the location of the magnified follicle (inset image) where the white scale bar is 500µm. Figure 7F is an H&E stain of dorsal murine skin following high temperature cautery depicting removal of epidermal, dermal and hypodermal tissues including the follicular bulge. Figure 7G is DAPI/DNA stain (4',6-diamidino-2-phenylindole) of non-burned, intact skin with hair follicle and adnexal structures. The arrow indicates the magnified follicle with co-labeling of immunofluorescent LGR5 and LGR6 antibodies green and red respectively (inset image). Figure 7H DAPI/DNA stain of dorsal murine skin following high temperature cautery depicting removal of epidermal, dermal, and

hypodermal tissues including the follicular bulge where the white scale bar is 100  $\mu\text{m}$ .

Figures 8A-Q depict a wound/injury/void with LGR as it relates to antimicrobial behavior over five and ten day time periods. Using 16S rRNA fluorescent oligonucleotide probes, in-situ hybridization indicates the presence of bacterial adhesion at the third degree burn wound bed. Figure 8A presents DNA/DAPI labeling of a 3rd degree burn wound bed at day five post burn induction treated daily with SDZ. In Figure 8B 5'- Cy3-EUB338 labeled 16s rRNA of 3rd degree burn wound bed bacterial organisms (yellow grains) at day five post burn induction treated daily with SDZ are depicted. Figure 8C is a digitally merged image of Figures 8A and 8B. Figure 8D corresponds to Figure 8A except at day ten with DNA/DAPI labeling of 3rd degree burn wound bed treated daily with SDZ. Correspondingly, Figure 8E is a photomicrograph of the 5'- Cy3-EUB338 labeled 16s rRNA of 3rd degree burn wound bed bacterial organisms (yellow grains) at day ten post burn induction treated daily with SDZ. Figure 8F is a merged image of Figures 8D and E. Figures 8G-8L are images corresponding respectively to the five and ten post burn periods of Figures 8A-F but subject to daily treatment using Defensin, alpha 5 (DEFA5) rather than SDZ. The arrow in H represents the interface of tissue with overlying fibrinous material where less bacteria is observed in the setting of DEFA5 treatment. Figure 8M with inset 8N demonstrate quantification of white pixel intensity of Cy3 fluorescence grayscale converted image of a wound bed treated with SDZ and containing more 16s rRNA labeling per unit area. Figure 8O and inset 8P correspondingly show quantification of white pixel intensity of Cy3 fluorescence grayscale converted image of (inset image p.) a wound bed treated with DEFA5 and containing a reduced 16s rRNA labeling per unit area. The inset graph depicts averaged white pixel intensity of 16s rRNA expressed in both SDZ and DEFA5 treated burn wound beds at day five using grayscale imaging software. Finally, Figure 8Q is a graph to illustrate averaged red channel fluorescence of 16s rRNA expressed in both SDZ and DEFA5 treated burn wound beds at day five. The white arrow in Figure 8H indicates potential film in DEFA5 treated wound beds and the black arrow in Figure 8M indicates white pixel intensity. Scale bar 100 $\mu\text{m}$ . (\*) indicates p-value <0.05.

Figures 9A and B are a series of time progression photographs that represents an example of LGR expressing cellular entities within wound as it relates to augmented healing, tissue and appendage regeneration and subsequent hair growth, wound healing kinetics and nascent hair growth in treated burn wounds devoid of adnexal structures. The photographic series comprising Figure 9A are gross imaging using a Leica Wild M680 surgical microscope to image healing of 3rd degree burn wound beds over 10 days while being treated with indicated agents MQH2O, DEFA5, DEFB1, SDZ. The white scale bar represents 1mm. The second photographic series of Figure 9B again comprises gross imaging using a Leica Wild M680 to track nascent hair growth of 3rd degree burn wound beds over 16 days in a side by side comparison of DEFA5 vs. control treated wound beds. The white arrows indicate the growth of new hair. Again, the scale bar is 1mm.

Figures 10A-L comprise an example of said LGR expressing cellular entities within wound/injury/ tissue void as it relates to augmented healing, propagation of said entities. The Graphs comprising Figures 10K and 10L provide evidence of quantification of wound bed healing kinetics and LGR5 and LGR6 stem cell migration into burn tissue following treatment with topical focal agents. Briefly, these tests were used to confirm the quantitative confocal microscopic intensity patterns from imaging LGR5 and LGR6, and based on reverse-transcriptase polymerase chain reaction on burn wound tissues. As represented in the graphs, averaged LGR5 and LGR6 mRNA expression within human alpha defensin 5 wound beds was found to be  $95.8 \pm 10.6$  and  $259.2 \pm 20.2$ , respectively, compared with undetectable levels of LGR5 and LGR6 in sulfadiazine-treated wounds at day 5 (Fig. 4, *right*). The magnitudes of these fold-level comparisons within human alpha defensin 5-treated tissues and those specimens treated with sulfadiazine suggest that it is the absolute presence or void of cells expressing LGR5 and LGR6 migrating into the wound that defines the fold values.

Turing to the specific figures, Figure 10A presents photographs of a wound area with a white scale bar representing 1mm and the wound area calculation in black. Figure 10B graphically displays the averaged wound healing rate expressed as percent % of wound area remaining over 10 day

period of indicated topical focal agent application. The asterisk (\*) represents a p-value <0.05. Figures 10C-J are LGR5 and LGR6 immunofluorescent antibody labeling of a DEFA5 treated wound bed at day 5 where Figure 10C is DNA/DAPI/Blue, Figure 10D is LGR5/FITC/Green Figure 10E is LGR6/TRITC/Red and Figure 10F is a merger of 10C-10E. Figures 10G-I are corresponding LGR5 and LGR6 immunofluorescent antibody labeling of SDZ (sulfadiazine) treated wound bed at day 5 (DNA/DAPI/Blue, LGR5/FITC/Green and LGR6/TRITC/Red). Figure 10J is a merged image of 10G-10I and includes an inset representing averaged LGR5 and LGR6 expression using Green and Red fluorescent intensity per wound bed at day 5. The comparative values obtained from Reverse Transcriptase PCR quantification of the fold increase in RNA extracted from replicate wound beds treated with DEFA5 and SDZ is set out. The white scale bar 50µm and again, the asterisk (\*) represents a p-value <0.05.

Figures 11A and B illustrate a wound/injury/tissue void with the LGR expressing cellular entities placed within wound as it relates to augmentation of pro-healing pathways. The figures respectively represent RT-PCR quantification and gene heat mapping comparison of wound beds treated with DEFA5 to SDZ. These figures show the role of human alpha defensin 5 versus sulfadiazine in augmenting key transcript expression within the wound. The results show that several gene subsets are significantly up-regulated within the wound beds receiving human alpha defensin 5 when compared with sulfadiazine therapy and that certain Wnt pathway gene subsets are significantly up-regulated in response of the LGR stem cell system to Wnt ligands in both the gut and skin.

Figure 11A presents an Averaged Wound Healing RT2-PCR Array pathway heat map and corresponding gene map with fold regulation for wound beds comparing DEFA5 to SDZ treated systems. Figure 11B presents an Averaged Wnt RT2-PCR Array healing pathway heat map and corresponding gene map with fold regulation for wound beds comparing DEFA5 to SDZ treated systems. The colors of the heat maps are indicated as red, more expressed in DEFA5 treated burns to green more expressed in SDZ treated burns.

Figures 12A-I represent an example of a micro-aggregate multicellular unit containing LGR expressing stem cell foci as it relates to location, population

identity and wound healing capacity. Using a simple *ex vivo* wound healing assay and fluorescence-activated cell sorting, LGR6+, CD34+, and CD73+ C57BL/6(UBC-GFP) murine cells were isolated for cell culture expansion.

Figure 12A depicts LGR6 fluorescent antibody (green) expression of cells on the hair follicle following partial epidermal 10 unit/ $\mu$ L dispase digestion. (Worthington Biochemical Corp., Lakewood, N.J.) digestion for 30 minutes at 37°C on a slow rocker. Figure 12B is of LGR6+ cells expressing additional CD34 and CD73 markers (the arrow indicates population isolated comprising approximately 1 to 3 percent of all cells). Figures 12C-H are eFluor450 expression histograms of an *in vitro* wound assay respectively showing periodic intrinsic GFP expression from C57BL/6(UBC-GFP) murine cells, CD34+ PE/Cy7 expression, LGR6+ APC expression and CD73+. The dotted lines indicates the distance of separation at 0, 6, and 12 hours following disruption of the cell layer and the scale bar = 50  $\mu$ m. The graph of Figure 12I sets out the averaged reduction in the distance line over time expressed as a percentage of initial distance following fluorescence sorting where the asterisk (\*) represents a p-value <0.05.

Figures 13A-D are photomicrographs by confocal microscopy and bioluminescence of an activated functional singularity unit (aFSU) at the time initial seeding and 1 day later showing an example of a micro-aggregate multicellular unit containing LGR expressing stem cell foci while undergoing initial propagation on a collagen matrix, Figure 13 E.

Figures 14A-E depict an example of location LGR cellular varieties as it relates to location, phenotype, interface and polarity within a cutaneous tissue. Figure 14A shows by Immunofluorescence staining, localized regions of LGR6 (Green/fluorescein isothiocyanate (FITC)) and LGR5 (Red/tetramethyl rhodamine isothiocyanate (TRITC)) expression. The scale bar is for 20 $\mu$ m. Figure 14B shows fluorescence-activated cell sorting isolation of the LGR6+<sup>GFP</sup> epithelial stem cells from C57BL/6(UBCGFP) murine skin with the final sort gate using LGR6+, CD34 and CD73 on the left and individual histograms depicting cellular GFP expression and correlating antibody-conjugate labels: CD73/PE-7, LGR6/Cy5, CD34/eFlour450 on the right. Figure 14C shows differential interference contrast image of LGR6+<sup>GFP</sup> epithelial stem cells plated following fluorescence-activated cell sorting isolation. Figure 14D depicts intrinsic GFP

expression of the LGR6<sup>+GFP</sup> epithelial stem cells and Figure 14E is a merged image of Figures 14C and 14 D. The scale bar represents 20µm.

Figures 15A-E provide an example of LGR expressing cellular foci as it relates to a method of delivery through placement around and/or within wound/injury/tissue void. The three images of Figure 15A depict, respectively,  
5 an initial burn template; a full thickness burn on the dorsum on Nu/Nu mouse; and delivery of Hydrogel® containing 10<sup>5</sup> LGR6<sup>+GFP</sup> epithelial stem cells at the base of the wound bed. The scale bar for Figure 15A is 1mm. Figure 15B is an immunofluorescence image of the injection pocket DNA/DAPI-BLUE at Day 0  
10 Figure 15B is an immunofluorescence image of anti-LGR6/TRITC antibody labeling and Figure 15C the same for LGR6<sup>+GFP</sup> epithelial stem cells. Figure 15 E is a merged image of Figures 15B-D and has a scale bar of 20µm. Figures 15A-E show full thickness burn wound bed induction and validation of LGR6+ stem cell engraftment into subsequent soft tissue defect.

Figures 16A-D depict an example of LGR containing stem cell focus as it relates to delivery into and around wounds via a deliverable vector and subsequent healing, regeneration of tissues and supporting structures including but not limited blood vessel angiogenesis and/or angiogenesis. Wound healing progression following LGR6+ epithelial stem cells transplantation into full  
20 thickness wounds. The progression of wound healing is depicted following the injection of Hydrogel from BD Biosciences, San Jose, Calif. (control) in Figure 16A compared with Figure 16B, LGR6<sup>+GFP</sup> epithelial stem cells seeded Hydrogel over 15 days. The scale bar is 1mm. In Figure 16C, showing the implant pocket after day 15, the white arrow indicates presence of a remaining LGR6<sup>+GFP</sup>  
25 epithelial stem cells population located within healing wound bed. In Figure 16D, the black arrow indicates the location of the burn wound base free of LGR6<sup>+GFP</sup> epithelial stem cells.

Figures 17A-D depicts an example of LGR containing stem cell focus following delivery into and/or around wound with subsequent healing and  
30 regeneration of tissues and related appendages such as but not limited to hair follicle and related supportive structures. Figure 17A is a four panel matrix of confocal images of immunofluorescent labeled tissue specimen at day 10 following transplantation of LGR6+ epithelial stem cells migration into the wound

bed 10 days. The images comprising Figure 17A include DNA/DAPI-BLUE; anti-LGR6/TRITC; GFP expression of LGR6<sup>+GFP</sup> ESC.

Figure 17B is a differential interference contrast image merge of all channels. The Red arrow designates regions of nascent follicle development. (See also the upper inset image). The dotted line shows epithelial polarization overlying nascent hair follicles while the white arrow indicates the location of the graft injection pocket (See also the magnification thereof in the lower inset image for an image of the initial injection pocket cellular population. The inset graph of Figure 17B represents comparative KRT17/ cytokeratin 17 gene expression within the indicated wound beds of the control and LGR6<sup>+GFP</sup> treatment.

Referring to Figure 17C, the three images are of a Transplant dome used to cover hair follicle study population burn wound beds, an LGR6<sup>+GFP</sup> ESC treated wound bed at day 10 (solid arrow) with nascent hair follicles (clear arrow) follicle cyst formation and a control wound bed at day 10. The graph comprising Figure 17D quantifies the Day 10 wound bed resulting from RT-PCR indicating relative gene fold expression of WNT ligands. The positive numbers indicated higher expression in LGR6<sup>+GFP</sup> epithelial stem cells wound beds while the negative numbers indicate higher expression in control wound beds.

Figure 18 provides an RT-PCR quantification and inset gene heat mapping comparison of a wound/injury/tissue void with the LGR expressing cellular foci as it relates to delivery into and/or around wound/injury/tissue void as it relates to augmentation of pro-healing pathways and comparative gene expression of wounds receiving LGR6+ epithelial stem cells against a control. The graphs illustrate the relative fold expression of genes for angiogenesis, wound healing and epidermal growth factor. Correlative graphical representation of data comparing wound beds receiving LGR6+ epithelial stem cells and control therapy. As to the inset heat maps the color red indicates greater expression within the LGR6+ epithelial stem cell wound bed while the color green indicates greater expression within the control wound bed. In the bar graphs, positive numbers indicated higher expression in LGR6<sup>+GFP</sup> epithelial stem cell wound beds and negative numbers indicate higher expression in control wound beds. The NCBI Unigene term is indicated at the top of each quantitative column and the asterisk (\*) P-value designates <0.05 significance.

Figure 19 graphically presents the relative protein densitometry of an example of LGR expressing cellular foci as it relates to delivery into and/or around wound/injury/tissue void and augmentation of wound healing factors.

Comparative angiogenesis analyte expression of wounds receiving LGR6+ ESCs Proteomic array comparing common proteins which regulate and augmented angiogenesis. The grey columns indicate control wounds and the black columns indicated those wounds that received the LGR6<sup>+GFP</sup> ESC. The inset image shows example proteome array membranes following development with HRP chemi-luminesce. Brighter colors indicate higher levels of protein expression.

Figures 20A-F illustrate an example of LGR expressing cellular foci as it relates to the regeneration of bone tissues. Isolated LGR foci can be seeded bone and remain viable. Figure 20A is a gross bone image of harvested bone for culture. Figure 20B is a DIC image of bone containing LGR GFP 7 days following seeding. Figure 20C is a 488 nm Green laser confocal image of bone containing LGR6<sup>+GFP</sup> 7 days following seeding. It is notable that the LGR foci can undergo osteo-induction in-vitro. Figure 20D depicts LGR foci following 1 week of osteo-induction with supplemental media. Figure 20E is an Alizarin red stain of the LGR foci following osteo-induction which can undergo osteo-induction in-vitro and up regulate key osteogenic genes. Finally, Figure 20F is RT-PCR data showing relative fold gene expression where the grey columns represent (control) non-osteo induced LGR and the black columns represent those LGR which received osteo-induction media following 7 days of culture. GAPDH was used as reference standard housekeeping gene.

#### EXEMPLARY PROTOCOL

The following is a series of examples providing an illustrative protocol sequence for practice of an embodiment of the invention.

Prior to generation of the minimally polarized functional units in accordance with the invention, a gelatinous support such as an exemplary three dimensional collagen scaffold can be generated by well-known processes as follows:

i. Slowly adding 1 part of chilled 10X PBS of 10X culture media to 8 parts of chilled collagen-based solution with gentle swirling. Adding ECM and viability proteins to the suspension;

5 ii. Adjusting the pH of mixture to 7.2-7.6 using sterile 0.1M NaOH and monitoring the pH adjustment carefully;

iii. Adjusting the final volume to a total of 10 parts with sterile molecular grade water;

iv. Maintaining temperature of mixture at 2 – 10°C to prevent gelation,

v. Forming a gel by warming to 37°C for approximately 90 to 120 minutes;

10 vi. Perforating the scaffold with a sterile micro-needle press (the scaffold can undergo freeze drying process if needed for storage).

It is also recommended that an additional material referred to as Pulse Resource Media (PRM) be produced and be available prior to commencement of the LGR aggregate extraction procedures.

15 The PRM, in this embodiment which is direct to humans, is a cell sustaining, serum-free, media mixture Keratinocyte-SFM containing L-glutamine supplied with separately packaged prequalified human recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and Bovine Pituitary Extract (BPE) sold as Keratinocyte-SFM (1X) from Thermo Fisher Scientific to which the antibiotic-antimycotic agents penicillin, streptomycin, and amphotericin B are added along  
20 with a GMP- fibrinogen: human. The agent used in one embodiment is Gibco® Antibiotic-Antimycotic from Thermo Fisher Scientific, a solution containing 10,000 units/mL of penicillin, 10,000 µg/mL of streptomycin, and 25 µg/mL of Fungizone® Antimycotic. Because the PRM is used to transport human tissues,  
25 the supplemental reagents are utilized to stabilize the primary tissues and reduce the viability of micro-organisms during transport and processing.

The following relates specifically to the generation and preservation of LGR expressing epithelial containing stem cell micro-aggregate functional units in accordance with an embodiment of the invention.

### 30 **Example 1**

Example 1 concerns a method for extraction of minimally polarized functional units in accordance with an embodiment of the invention. After

obtaining a specimen, it is removed from its associated transport container followed by:

i. Placing the specimen into a sterile 50 ml conical tube containing pulse rescue media and placed on rocker for 5 minutes, repeat with fresh media and container for total of three times;

ii. Removing and placing the specimen into a sterile culture dish containing pulse media and excise fat and hypodermal elements from the dermal and epidermal compartments carefully. Follicular units are left in place and are not overly dissected;

iii. Placing excised hypodermal fat components into separate a 50ml conical tube containing PRM and place in +4°C on slow rocker.

iv. Sectioning the remaining cutaneous elements containing epidermal, follicular and dermal compartments into minimal polarized functional units (MPFUs) using ultrafine WecPrep Blades or some form of micro-16 lancet; and

v. Placing the MPFUs components into separate a 50ml conical tube containing pulse media and place in +4°C.

The following relates to secondary processing where the primary cultures are established and functional tissue elements are prepared utilizing enzymatic preparation using conventional CLIA equipment and reagents meeting FDA and/or GMP certification:

### **Example 2**

Example 2 is directed to processing of hypodermis and subdermal fat cellular components. Example 2 recites the following steps:

i. Spraying 70% ethanol (EtOH) on the outer side of the tissue container and placing the tissue container into laminar air flow cabinet;

ii. Sending a sample of the tissue or transfer medium for microbiological testing;

iii. Placing the previously washed adipose and hypodermal tissue in 150mm sterile petri dish;

iv. Washing the tissue two times with PRM;

v. Trimming the tissue into small (3mm) pieces with sterile surgical instrument and place into sterile culture holding dish containing pulse media while the dissection is completed;

vi. Aspirating media from holding dish and removing the specimen with sterile scoop or forceps followed by placing the specimen into 50 ml conical tube containing MSC Enzymatic Digestive Media, a pre-mixed digestive enzyme solution (collagenase and dispase-based), which is placed into a 37°C water bath or dry heat slow shaker and shaken for 30 minutes or until there are few particulate materials remaining;

vii. Adding 37°C phosphate buffer saline (PBS) ethylenediamine tetraacetic acid (EDTA) (equal volume PBS-EDTA) to stop the digestion;

viii. Centrifuging the suspension for 10 minutes to generate a “soft” pellet;

ix. Discarding upper liquid portion and using a sterile pipette, separating the adipose population from stromal vascular fraction (SVF) in the saved mass;

x. Re-suspending the SVF in phosphate buffer saline/EDTA, PBS-EDTA (1 mM of EDTA), and re-suspending adipocyte population in PRM in two separate conical tubes;

xi. Using 100 µm sterile, filter the suspension into new sterile conical tubes;

xii. Washing the filter with PBS-EDTA;

xiii. Spin filtering the suspension for 10 minutes at room temperature followed by aspiration of the media and replacing the aspirated media with a known volume of fresh media;

xiv. Using a Countess™ automated cell counter (Thermo Fisher Scientific), count cell populations to determine viability;

xv. Removing 20% of obtained cell population for cryopreservation with Syntha-Freeze CTS™ (Cell Therapy Systems) from Thermo Fisher Scientific and subsequently cataloguing appropriately while using the remaining 80% population for construct assembly.

### Example 3

Example 3 is directed to addition of hypodermis and subdermal fat components to the example of a construct according to an embodiment of the invention. The illustrative component addition example involves:

i. Placing a sterile Nunc Skin Graft Cell Culture Dish or automated dish already containing the assembled and washed scaffold into a laminar flow hood and washing the scaffold again two times with pulse media prior to adding cells;

- ii. Inserting a label on each culture vessel with tracking number;
- iii. Transferring around  $5 \times 10^5$  to  $1 \times 10^6$  mixed SVF cells per dish system and  $1 \times 10^5$  adipocytes per dish;
- iv. Adding a complete culture medium with or without autologous PRP as dictated by the particular requirements of a situation, to the loading reservoir;
- v. Transferring the dishes into an incubator onto slow rocker for 1 hour followed by removal therefrom and resting flat for 48 hours in separate sentinel incubator;
- vi. Washing the culture medium after 48 hours, discarding the non-adherent cells, and renewing the complete culture medium. Image with a cell imaging device such as an EVOS (ThermoFisher Scientific) and store with the designated tracking number.
- vii. Every 72 hours replacing the culture medium;
- viii. At confluence, washing the culture with Dulbecco's phosphate-buffered saline (DPBS) and replacing the culture media with fresh media.
- ix. Placing the epithelial stem cell functional singularity constructs (ESC FSUs) directly on the surface of the mesenchymal stem cell (MSC) construct, adding ESC media to cover both constructs, imaging the same and replacing the construct into the incubator.
- x. Changing/replacing the construct media every 48 hours.

#### **Example 4**

Example 4 concerns enrichment of the minimally polarized, epithelial stem cell singularity units. Following Example 1, the MPFUs is placed in pulse rescue media in a 15 ml conical tube and spin/centrifuged into a soft pellet. The material is then subject to the following process of partial digestion:

- i. Obtaining a previously aliquoted frozen 10ml digestion buffer (collagenase and dispase-based), which has been brought to room temperature prior adding to MPFUs;
- ii. Adding the digestion solution to the soft pellet of MPFUs and gently mixing, by flicking, the tube to allow MPFUs to distribute throughout the solution;
- iii. Placing the tube into  $37^\circ\text{C}$  water bath or dry incubator for 10 minutes;

iv. Removing the tube from the bath/incubator, gently flicking tube and examining the content for string;

v. Having observed string, centrifuging the content into a soft pellet;

5 vi. Washing the cell pellet in 5-10 mL complete Defined Keratinocyte SFM medium (Keratinocyte-SFM (1X) from ThermoFisher Scientific) and centrifuging into soft pellet again;

vii. Re-suspending the pellet of activated functional singularity units in 5 mL of complete the Keratinocyte-SFM medium; and

10 viii. Determining the cell density of the units using a Countess® Automated Cell Counter (ThermoFisher Scientific).

### **Example 5**

Example 5 involves adding the epithelial stem cell functional singularities (ESC aFSUs) obtained from Example 4 to a construct/scaffold. The procedure entails:

15 i. Placing an Upcell Surface Skin Graft Cell Culture Dish already containing an assembled and washed scaffold, and to assure physiologic pH, washing the scaffold twice again with pulse media prior to adding the cells;

ii. Labelling each culture vessel with a unique tracking number;

20 iii. Transferring ESC aFSUs to the construct via disposable transfer pipette using complete Defined Keratinocyte SFM medium (additional autologous PRP is optional);

iv. Adding the complete culture medium to a select loading reservoir and ensuring complete coverage of the construct;

25 v. Transferring dishes into the incubator onto slow rocker for 1 hour. Then remove from rocker and allow to remain flat for 48 hours in separate sentinel incubator;

30 vi. At 48 hours, aspirating the culture medium and adding fresh Keratinocyte SFM culture medium. Imaging the culture with EVOS and storing the culture with the assigned tracking number. Increasing the gingival fibroblasts (GF) population and viability protein and/or supplementing the PRP if a need is detected at this time.

vii. Replacing the culture medium every 48-72 hours;

viii. Upon achieving confluence, washing the culture with DPBS and replacing the media. Reducing the temperature using temperature based system of the ESC construct scaffolding to facilitate release from the dish;

ix. Placing the ESC directly on the surface of the MSC construct and adding combined media to cover both constructs. Imaging the construct, placing it back into the incubator and changing the construct media every 48 hours.

x. To confirm polarization maintenance, imaging the construct daily and adding an appropriate Cornification (rind forming) medium following confirmation that polarization has been maintained for 48 hours;

xi. Washing the construct twice with pulse media at harvest and replacing the media with a defined transport media using CTS™ StemPro® MSC SFM base.

### Example 6

Example 6 represents illustrative protocols for quality assurance and construct finalization involving cryopreservation which entails preparation the construct for shipment following defined good manufacturing processes (GMP) for cell therapy applications and include:

i. Obtaining an appropriate volume of Synth-a-Freeze® cryopreservation medium (Thermo Fisher Scientific) and storing the medium at 2°C to 8°C until use;

ii. Preparing, harvesting and determining cell density using Countess® Automated Cell Counter prior to centrifugation a desired quantity of cells where typical cell densities for cryopreservation with Synth-a Freeze® medium are  $5 \times 10^5$  to  $3 \times 10^6$ ;

iii. Re-suspending the cell pellet in the pre-determined volume of 2°C to 8°C of Synth-a-Freeze® medium;

iv. Immediately dispensing aliquots of the obtained suspension into cryovials according to the manufacturer's specifications;

v. Placing the cryovials into an appropriate cryosystem, such as a Mr. Frosty™ system available from Thermo Fisher Scientific Inc. that maintains freezer temperatures at -80°C;

vi. Transferring the vials to a liquid nitrogen long-term vapor-phase storage at -200°C to -125°C.

The described embodiments of the invention have been provided in the foregoing specification. It should be understood by those skilled in the art that many modifications and embodiments of the invention will come to mind to which the invention pertains, having benefit of the teaching presented in the foregoing description and associated drawing. Therefore, it also should be understood that the invention is not limited to the specific embodiments disclosed herein, and that many modifications and other embodiments of the invention are intended to be included within the scope of the invention. Moreover, although specific terms are employed herein, they are used only in generic and descriptive sense, and not for the purposes of limiting the description invention.

### **Industrial Applicability**

The invention relates to methods for making and methods for using constructs of micro-aggregate multicellular grafts containing isolated Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for the delivery, application, transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating and/or injection of the cellular element generating, regenerating, enhancing and/or healing epithelial systems, glands, hair, nerves, bone, muscle, fat, tendons, blood vessels, fascia, ocular tissues and peptide secreting cellular elements for use in wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications.

**I claim:**

1. A minimally polarized micro-aggregate multi-cellular composition,  
5 characterized by:

a multi-dimensional support selected from the group consisting of scaffolding,  
collagen, matrix, particle, and fiber, and  
isolated living LGR expressing cells.

10 2. The composition of claim 1 further characterized by including growth  
factors and the LGR expressing cells being selected from the group consisting of  
LGR4, LGR5 and LGR6.

15 3. The composition of claim 1 further characterized by including  
migratory/recruiting analytes and the LGR expressing cells being selected from  
the group consisting of LGR4, LGR5 and LGR6.

20 4. The composition according to any one of claims 1 to 3 further  
characterized by including LGR specific binding elements selected from the  
group consisting of ligand families, R-spondin, EDGF, PDGF, Wnt, VEGF, and  
antimicrobial peptides and where the LGR expressing cells are selected from the  
group consisting of LGR4, LGR5 and LGR6.

25 5. A composition according to any one of claims 1 to 3 further characterized  
in that the composition is used for a therapeutic construct for any one of a tissue  
region, wound, void, defect tissue, or blood.

30 6. A composition according to any one of claims 1 to 3 further characterized  
in that the composition is used as a therapeutic construct for alteration of  
surrounding adjacent tissues.

7. A composition according to any one of claims 1 to 3 further characterized  
by the multi-dimensional support and isolated living LGR expressing cells

providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.

5 8. A composition according to any one of claims 1 to 3 further characterized by the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for tissue system repair or restoration throughout the body.

10 9. A tissue graft comprising a composition according to any one of claims 1 to 3 for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body.

15 10. A method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue.

20 11. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to claim 10 further characterized by the step of affixing the isolated living LGR expressing cells to a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber.

25 12. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to claim 10 further characterized by the step of selecting the LGR expressing cells from the group consisting of LGR4, LGR5 and LGR6.

30 13. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of claim 12 further characterized by the step of applying the minimally polarized micro-aggregate multi-cellular composition directly to a tissue *in vivo* for tissue restoration.

14. The method for obtaining a minimally polarized micro-aggregate multi-

cellular composition of claim 12 further characterized by the step indirectly applying the minimally polarized micro-aggregate multi-cellular composition via the blood stream for tissue restoration in a body.

5           15. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of claim 12 further characterized by the step of applying the minimally polarized micro-aggregate multi-cellular to one of the group consisting of epithelial systems, glands, hair, nerves, bone, muscle, fat, tendons, blood vessels, fascia, ocular tissues and peptide secreting cellular elements employing  
10 delivery by a technique selected from the group consisting of application, transplantation, implantation, directed seeding, directed migration, directed tracking, in setting, laminating and/or injection of the cellular element generating, regenerating, enhancing and healing.

15           16. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of claim 12 further characterized by the step of supplementing the composition with one or more supplements selected from the group consisting of growth factors, migratory analytes, recruiting analytes and LGR specific binding elements.

20           17. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of claim 16 further characterized by selecting the supplement from the group consisting of ligand families: R-spondin, EDGF, PDGF, Wnt, VEGF, and antimicrobial peptides.

25           18. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to any one of claims 10 to 12 further characterized by the step of transplanting the composition to a tissue wound for accelerated healing thereof.

30           19. A method of producing a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of:

a) obtaining a tissue specimen;

b) extracting minimally polarized functional units containing LGR expressing cells from the specimen;

c) processing of hypodermis and subdermal fat cellular components from an appropriate source;

5 d) adding the processed hypodermis and subdermal fat components to the extracted minimally polarized functional units to create epithelial stem cell singularity units;

e) enriching the epithelial stem cell singularity units;

f) adding the epithelial stem cell singularity units to a construct scaffold; and

10 g) verifying the maintenance of minimum polarization of the obtained composition.

20. The method of claim 19 for producing a minimally polarized micro-aggregate multi-cellular composition further characterized by the steps of  
15 subjecting the epithelial stem cell singularity units to digestion and the confirming microaggregate confluence before verification.

21. The method of claim 20 for producing a minimally polarized micro-aggregate multi-cellular composition further characterized by the step of adding  
20 an appropriate cornification medium following confirmation that polarization has been maintained for 48 hours.

22. The method of any one of claims 19 to 21 for producing a minimally polarized micro-aggregate multi-cellular composition further characterized by the  
25 step of cryopreserving the obtained composition.

23. A cell sustaining media composition for reducing the viability of micro-organisms during transport and processing of tissues, characterized by

a) a mixture of epithelial cells and keratinocytes,

30 b) at least one agent selected from the group consisting of penicillin, streptomycin, and amphotericin B, and

c) fibrinogen.

24. The cell sustaining media composition of claim 23 where the fibrinogen is human and where the agent includes both an antibiotic and an antimycotic for stabilizing human tissues.

5           25. A composition according to claim 4 further characterized in that the composition is used for a therapeutic construct for any one of a tissue region, wound, void, defect tissue, or blood.

10           26. A composition according to claim 4 further characterized in that the composition is used as a therapeutic construct for alteration of surrounding adjacent tissues.

15           27. A composition according to claim 4 further characterized by the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.

20           28. A composition according to claim 4 further characterized by the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for tissue system repair or restoration throughout the body.

25           29. A tissue graft comprising a composition according to claim 4 for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body.

30           30. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to claim 16 further characterized by the step of transplanting the composition to a tissue wound for accelerated healing thereof.

30           31. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to claim 17 further characterized by the step of transplanting the composition to a tissue wound for accelerated healing thereof.




FIG. 1A

FIG. 1B




FIG. 1C




FIG. 2A

FIG. 2B




FIG. 3A FIG. 3B FIG. 3C FIG. 3D FIG. 3E FIG. 3F

4/27




FIG. 4A





FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E

FIG. 5A FIG. 5B FIG. 5C




FIG. 5D




FIG. 5E

6/27




FIG. 6A

7/27




FIG. 6B




FIG. 7A




FIG. 7B



FIG. 7C




FIG. 7D




FIG. 7F




FIG. 7E




FIG. 7G






FIG. 7H

9/27



DNA  
**FIG. 8A**

Day 10




DNA  
**FIG. 8D**

Day 5




DNA  
**FIG. 8G**

Day 10




DNA  
**FIG. 8J**




Bacterial 165 rRNA  
**FIG. 8B**

Day 10




Bacterial 165 rRNA  
**FIG. 8E**

Day 5




Bacterial 165 rRNA  
**FIG. 8H**

Day 10




Bacterial 165 rRNA  
**FIG. 8K**




Merge  
**FIG. 8C**

Day 10



Merge  
**FIG. 8F**

Day 5



Merge  
**FIG. 8I**

Day 10



Merge  
**FIG. 8L**

10/27

FIG. 8M

FIG. 8N





FIG. 8P




FIG. 8O





FIG. 8Q


11/27

FIG. 9A



12/27

FIG. 9B



13/27




FIG. 10A




FIG. 10B





FIG. 10F




FIG. 10J

15/27

LGR 5 Wound Bed Expression




FIG. 10K

LGR 6 Wound Bed Expression





FIG. 10L

16/27

Wound Healing  
RT-PCR  
Gene Array


FIG. 11A




17/27


Wnt pathway  
RT-PCR  
Gene Array

FIG. 11B






DIC, Lgr6/FITC  
**FIG. 12A**




**FIG. 12B**




GFP+Lgr6,CD34,CD73

**FIG. 12C**




GFP+Lgr6,CD34,CD73

**FIG. 12D**




GFP+Lgr6,CD34,CD73

**FIG. 12E**




GFP+Lgr6,CD34,CD73

**FIG. 12F**



GFP+Lgr6,CD34,CD73

**FIG. 12G**



GFP+Lgr6,CD34,CD73

**FIG. 12H**

19/27




FIG. 12I

FIG. 13A FIG. 13B





FIG. 13C

FIG. 13D

FIG. 13E

20/27

FIG. 14A



Final Sort Gate





FIG. 14B



DIC


LGR6 +GFP ESC

Merge

FIG. 14C

FIG. 14D

FIG. 14E





Engraftment

FIG. 15A

FIG. 15B

FIG. 15C

FIG. 15D



Merge

FIG. 15E

22/27




FIG. 16A

FIG. 16B

Day 15 Implant Pocket



FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B

24/27




FIG. 17C




FIG. 17D

25/27






FIG. 19




27/27



Gross Bone  
**FIG. 20A**


DIC Bone  
**FIG. 20B**

LGR6 +GFP  
**FIG. 20C**



DIC Bone  
**FIG. 20D**

Alizarin Red  
**FIG. 20E**



**FIG. 20F**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/063114

<p><b>A. CLASSIFICATION OF SUBJECT MATTER</b>                  IPC(8) - C12N 5/02 (2016.01)                  CPC - C12N 5/0602 (2016.02)                  According to International Patent Classification (IPC) or to both national classification and IPC</p>																							
<p><b>B. FIELDS SEARCHED</b></p> <p>Minimum documentation searched (classification system followed by classification symbols)                  IPC(8) - C12N 5/02, 5/071, 5/00, 1/00, 1/38 (2016.01)                  CPC - C12N 5/0018, 5/0671, 5/0677, 5/068, 2501/415 (2016.02)</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                  USPC - 435/325, 371, 384, 405 (keyword delimited)</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                  PatBase, Google Patents, Google Scholar, Pub Med                  Search terms used: epithelial stem cell aggregate micro-aggregate organoid LGR LGR4 LGR5 LGR6 scaffolding collagen matrix particle fiber</p>																							
<p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>US 2012/0196312 A1 (SATO et al) 02 August 2012 (02.08.2012) entire document</td> <td>1-18, 25-31</td> </tr> <tr> <td>Y</td> <td>US 2006/0240555 A1 (RONFARD) 26 October 2006 (26.10.2006) entire document</td> <td>23, 24</td> </tr> <tr> <td>Y</td> <td>US 2009/0280095 A1 (SZABOWSKI et al) 12 November 2009 (12.11.2009) entire document</td> <td>23, 24</td> </tr> <tr> <td>A</td> <td>WO 2014/159356 A1 (THE BRIGHAM AND WOMEN'S HOSPITAL, INC. et al) 02 October 2014 (02.10.2014) entire document</td> <td>1-31</td> </tr> <tr> <td>A</td> <td>WO 2006/008009 A2 (BAYER HEALTHCARE AG) 26 January 2006 (26.01.2006) entire document</td> <td>1-31</td> </tr> <tr> <td>A</td> <td>LOUGH et al. "Development of a Chimeric Free Flap Allograft Using the LGR6+ Epithelial Stem Cell," Plast Reconstr Surg. March 2014, Vol. 133(3 Suppl), Pgs. 120-1. Abstract Only.</td> <td>1-31</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US 2012/0196312 A1 (SATO et al) 02 August 2012 (02.08.2012) entire document	1-18, 25-31	Y	US 2006/0240555 A1 (RONFARD) 26 October 2006 (26.10.2006) entire document	23, 24	Y	US 2009/0280095 A1 (SZABOWSKI et al) 12 November 2009 (12.11.2009) entire document	23, 24	A	WO 2014/159356 A1 (THE BRIGHAM AND WOMEN'S HOSPITAL, INC. et al) 02 October 2014 (02.10.2014) entire document	1-31	A	WO 2006/008009 A2 (BAYER HEALTHCARE AG) 26 January 2006 (26.01.2006) entire document	1-31	A	LOUGH et al. "Development of a Chimeric Free Flap Allograft Using the LGR6+ Epithelial Stem Cell," Plast Reconstr Surg. March 2014, Vol. 133(3 Suppl), Pgs. 120-1. Abstract Only.	1-31
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																					
X	US 2012/0196312 A1 (SATO et al) 02 August 2012 (02.08.2012) entire document	1-18, 25-31																					
Y	US 2006/0240555 A1 (RONFARD) 26 October 2006 (26.10.2006) entire document	23, 24																					
Y	US 2009/0280095 A1 (SZABOWSKI et al) 12 November 2009 (12.11.2009) entire document	23, 24																					
A	WO 2014/159356 A1 (THE BRIGHAM AND WOMEN'S HOSPITAL, INC. et al) 02 October 2014 (02.10.2014) entire document	1-31																					
A	WO 2006/008009 A2 (BAYER HEALTHCARE AG) 26 January 2006 (26.01.2006) entire document	1-31																					
A	LOUGH et al. "Development of a Chimeric Free Flap Allograft Using the LGR6+ Epithelial Stem Cell," Plast Reconstr Surg. March 2014, Vol. 133(3 Suppl), Pgs. 120-1. Abstract Only.	1-31																					
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C.      <input type="checkbox"/> See patent family annex.</p>																							
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed												
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																						
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																						
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																						
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family																						
"P" document published prior to the international filing date but later than the priority date claimed																							
<p>Date of the actual completion of the international search 25 February 2016</p>		<p>Date of mailing of the international search report <b>04 MAR 2016</b></p>																					
<p>Name and mailing address of the ISA/ Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300</p>		<p>Authorized officer <b>Blaine R. Copenheaver</b> PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774</p>																					

## 摘要

本文提供的是微聚集體多細胞、最小極性化移植物的構建體，其含有表達含有富含亮氨酸重複序列的 G-蛋白偶聯受體(LGR)的細胞，用於傷口治療應用、組織工程學、細胞療法應用、再生醫學應用、醫學/治療應用、組織愈合應用、免疫療法應用和組織移植療法應用，其優選與遞送載體/基底/支持物/支架聯合以用於直接施用。